Lesson
Name the Syndrome Before the Cause
Cognitive symptoms become a disorder when they represent decline from baseline and affect efficiency or independence, but acute inattention and fluctuation point toward delirium.
- Subjective decline
- MCI
- Dementia
- Delirium
- Function
cognitive syndrome
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Separate concern from impairment
Subjective cognitive decline can be meaningful even when testing is normal. Mild cognitive impairment requires objective decline while basic independence is preserved, although complex tasks may become less efficient.
Make function explicit
Dementia involves cognitive decline that interferes with independent daily function. Ask who manages medicines, bills, transportation, appointments, meals, technology, and emergencies rather than relying on labels.
Treat delirium as urgent
Abrupt onset, fluctuating attention, altered awareness, or a rapid change from baseline requires evaluation for acute medical, medication, substance, sensory, pain, sleep, and environmental causes.
Use collateral history
A trusted informant can describe trajectory, errors, safety events, personality change, fluctuations, and lost skills that a brief visit or screening score cannot show.
Quick check
Lesson
Build a Diagnostic Story, Not a Screening Score
A modern evaluation combines history, objective cognition, function, neurologic examination, medication and substance review, mood, sleep, laboratory testing, structural imaging, and etiologic testing when it will change care.
- History
- Cognition
- Function
- Laboratory
- Imaging
diagnostic workup
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Map cognitive domains
Assess memory, language, executive function, attention, visuospatial ability, social cognition, behavior, and motor features. The first and most impaired domain can refine the differential.
Interpret tests in context
MoCA, MMSE, Mini-Cog, and formal neuropsychological testing serve different purposes. Sensory impairment, language, education, culture, motor limitations, mood, fatigue, and practice effects alter performance.
Search reversible contributors
Review depression, sleep apnea, hearing and vision, thyroid disease, vitamin B12 status, infection when indicated, metabolic disease, seizures, substances, and medication toxicity. Structural imaging can identify vascular injury, mass, hydrocephalus, and atrophy patterns.
Recognize mixed disease
Alzheimer pathology frequently coexists with vascular, Lewy body, TDP-43, hippocampal sclerosis, or other pathology. A single clinical phenotype does not guarantee a single cause.
Quick check
Lesson
Connect Biology to the Clinical Stage
Alzheimer disease is increasingly defined through amyloid and tau biology, while symptoms reflect pathology, neurodegeneration, copathology, reserve, and the brain systems affected.
- Amyloid
- Tau
- Neurodegeneration
- Core biomarker
- Reserve
biology biomarkers
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Use current biological criteria
The 2024 criteria separate biological Alzheimer disease from the clinical syndrome. An accurate Core 1 biomarker can establish Alzheimer biology, while clinical staging independently measures symptom and functional consequence.
Choose validated tests
Amyloid PET and approved CSF biomarker profiles are established tools. Selected blood-based biomarkers can triage or confirm in specialty care only when assay performance meets current guideline thresholds.
Do not test without context
Current criteria recommend against routine diagnostic testing of cognitively unimpaired individuals outside research. Objective impairment, pretest probability, assay validity, counseling, and a next-step plan matter.
Respect discordance
A person can have biomarker-positive disease with few symptoms or significant impairment with multiple contributors. Biology and function must be documented separately.
Quick check
Lesson
Restore Cholinergic Signaling Without Promising Restoration
Donepezil, rivastigmine, and galantamine increase central acetylcholine by inhibiting cholinesterase, producing modest symptomatic benefit for some patients.
- Acetylcholine
- AChE
- BuChE
- Central exposure
- Symptomatic benefit
cholinergic system
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Follow the synapse
Acetylcholinesterase terminates acetylcholine signaling. Reversible inhibition extends transmitter action at surviving synapses but cannot replace lost neurons or reverse established neurodegeneration.
Recognize different scaffolds
Donepezil, rivastigmine, and galantamine are structurally distinct central agents. Donepezil is a selective reversible AChE inhibitor, rivastigmine inhibits AChE and BuChE through carbamylation, and galantamine also modulates nicotinic receptors.
Predict class effects
Increased cholinergic signaling explains nausea, vomiting, diarrhea, anorexia, weight loss, bradycardia, syncope, vivid dreams, urinary effects, and increased gastric secretion.
Set observable goals
Track cognition, daily function, behavior, participation, caregiver observations, weight, pulse, falls, gastrointestinal tolerance, and adherence. Stability may be meaningful, but benefit is not guaranteed.
Quick check
Lesson
Choose the Product the Patient Can Actually Use
Donepezil, rivastigmine, galantamine, and memantine differ by stage, formulation, organ function, administration, adverse effects, and caregiver workload.
- Donepezil
- Rivastigmine
- Galantamine
- Memantine
- Titration
symptomatic therapy
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Use donepezil deliberately
Donepezil is labeled across mild, moderate, and severe Alzheimer dementia. Titrate slowly and review bradycardia, conduction disease, syncope, weight loss, gastrointestinal effects, sleep disturbance, and interacting rate-slowing drugs.
Make the patch safe
Rivastigmine oral and transdermal products require specific titration. Remove the old patch before applying one new patch, rotate sites, check skin, and follow restart instructions after interruption.
Account for organ function
Galantamine requires renal and hepatic limits. Memantine is used for moderate to severe Alzheimer dementia and requires dose adjustment in severe renal impairment. Alkaline urine can reduce memantine clearance.
Avoid pharmacologic opposition
Strong anticholinergics can worsen cognition and oppose cholinesterase inhibitors. Review bladder drugs, antihistamines, antispasmodics, antipsychotics, tricyclics, and cumulative burden.
Quick check
Lesson
Audit Benefit and Burden Before Adding Another Drug
Cognition can worsen from anticholinergic load, sedatives, opioids, muscle relaxants, antiseizure drugs, polypharmacy, impaired clearance, hypotension, and prescribing cascades.
- Anticholinergic burden
- Sedation
- Falls
- Weight
- Deprescribing
medication safety
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Find the timeline
New confusion, falls, hallucinations, urinary retention, constipation, or functional decline after a medicine change requires exposure review before assuming irreversible disease progression.
Protect cardiac and nutritional reserve
Cholinesterase inhibitors can add to bradycardia, syncope, anorexia, and weight loss. Review beta blockers and other rate-slowing drugs, baseline conduction risk, falls, hydration, and weight trajectory.
Stop with a plan
Consider deprescribing when adverse effects are unacceptable, adherence is impossible, goals have changed, or no meaningful benefit remains. Taper and monitor because abrupt withdrawal can worsen cognition or behavior in some patients.
Reject unsupported supplements
Ginkgo, high-dose vitamin E, acetyl-L-carnitine, vinpocetine, and other products should not be presented as proven dementia therapy. Evaluate bleeding, interaction, product-quality, and opportunity-cost risks.
Quick check
Lesson
Treat Amyloid Only in the Population That Was Studied
Lecanemab and donanemab are current disease-targeting antibodies for early symptomatic Alzheimer disease with confirmed amyloid pathology and substantial monitoring requirements.
- MCI
- Mild dementia
- Amyloid confirmation
- MRI
- Shared decision
anti amyloid selection
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Define the labeled stage
Treatment should begin in mild cognitive impairment or mild dementia due to Alzheimer disease, matching the populations studied. These products are not established treatment for moderate or severe dementia.
Confirm the target
Amyloid pathology must be confirmed before treatment. A positive clinical impression alone is insufficient for a therapy directed at a biological target.
Explain effect honestly
These therapies slow decline on group-level outcomes rather than restore lost cognition. Infusion, MRI, adverse-event, cost, travel, and caregiver burdens must be weighed against the expected benefit.
Teach history accurately
Aducanumab approval was withdrawn effective November 1, 2024. It belongs in the history of the field, not a current treatment algorithm.
Quick check
Lesson
Make ARIA a Monitored System, Not a Footnote
Amyloid-related imaging abnormalities can involve edema or effusion, microhemorrhage, superficial siderosis, or larger hemorrhage and may be asymptomatic or stroke-like.
- ARIA-E
- ARIA-H
- APOE
- MRI
- Hemorrhage
aria monitoring
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Use the exact label
Obtain a recent baseline brain MRI and follow the current product-specific MRI schedule. Monitoring schedules and dose pathways differ between lecanemab and donanemab and can change with labeling.
Counsel on symptoms
Headache, confusion, visual change, dizziness, nausea, gait difficulty, focal weakness, seizure, or other acute neurologic change requires prompt evaluation and MRI when indicated.
Discuss APOE testing
APOE epsilon 4 homozygotes have higher ARIA incidence. Discuss genotype-linked risk and the personal and family implications of genetic information before testing.
Protect acute neurologic decisions
ARIA-E can mimic ischemic stroke. Anticoagulants, thrombolytics, pretreatment microhemorrhage, and superficial siderosis require high caution because serious and fatal hemorrhage has occurred.
Quick check
Lesson
Treat the Need Behind the Behavior
Agitation, aggression, hallucinations, delusions, sleep disruption, apathy, and wandering can arise from pain, delirium, fear, environment, communication failure, medication, or neurodegeneration.
- Trigger
- Pain
- Environment
- Psychosis
- Proportionality
behavioral care
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Describe before treating
Record what happens, when, where, with whom, what preceded it, what followed, and whether anyone is in danger. The word agitation is not a diagnosis.
Find reversible distress
Assess pain, constipation, urinary retention, infection, hunger, thirst, sleep, hearing, vision, overstimulation, loneliness, medication effects, and caregiver communication.
Use person-centered design
Simplify cues, preserve routine, offer meaningful activity, adjust lighting and noise, improve communication, and match care to history, preferences, culture, and ability.
Use antipsychotics proportionally
Antipsychotics increase mortality in older adults with dementia-related psychosis and can cause stroke, sedation, falls, metabolic effects, and motor worsening. Use a defined target, consent, monitoring, and reassessment.
Quick check
Lesson
Protect Independence by Naming the Actual Risk
Driving, medication management, cooking, finances, wandering, falls, firearms, exploitation, and emergency response require domain-specific assessment.
- Driving
- Medicines
- Finances
- Home
- Capacity
function safety
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Assess capacity by decision
Capacity is not erased by diagnosis. Evaluate the person's ability to understand, appreciate, reason, and communicate a choice for the specific decision with appropriate supports.
Make medicines usable
Simplify regimens, use packaging and reminders, confirm who fills and administers medicines, remove obsolete products, and protect against double dosing and unsafe access.
Address driving with evidence
Review crashes, near misses, getting lost, visual and motor function, cognition, collateral reports, and local requirements. Formal evaluation can support difficult decisions.
Plan before crisis
Advance directives, surrogate decision makers, finances, living preferences, emergency plans, and research or treatment preferences are best discussed while the person can participate fully.
Quick check
Lesson
Treat the Care Partner as Part of the Clinical System
Care partners contribute essential observations and labor while carrying their own risks of exhaustion, injury, depression, isolation, and financial strain.
- Collateral
- Education
- Respite
- Burnout
- Crisis plan
care partner system
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Use longitudinal evidence
Care partners often identify missed doses, unsafe driving, wandering, hallucinations, sleep disruption, functional loss, and adverse effects that are absent during clinic visits.
Teach concrete skills
Provide written and demonstrated guidance for patches, infusion appointments, MRI monitoring, communication, swallowing, falls, behavior response, and emergency symptoms.
Measure burden
Ask about sleep, mood, physical injury, work, finances, respite, backup help, confidence, and whether the current plan is sustainable.
Build redundancy
One exhausted person should not be the entire care infrastructure. Identify backup decision makers, medication support, transportation, respite, community resources, and crisis contacts.
Quick check
Lesson
Rebuild the Plan as the Disease Changes
Alzheimer and related dementias require repeated integration of biology, clinical stage, function, treatment response, safety, care capacity, equity, and goals.
- Trajectory
- Outcomes
- Equity
- Goals
- Palliative care
longitudinal care
Connect biology, clinical stage, function, safety, and the decisions each result changes.
Track what matters
Follow cognition alongside instrumental and basic function, behavior, falls, weight, pulse, sleep, driving, medication accuracy, caregiver burden, treatment logistics, and personally meaningful participation.
Reassess every therapy
Continue symptomatic or disease-targeting treatment only while indication, safety, monitoring capacity, and patient goals remain aligned. Product labels and evidence may change.
Address access and equity
Language, sensory disability, education, biomarker access, MRI availability, infusion travel, insurance, caregiver labor, and mistrust can alter both diagnosis and treatment feasibility.
Integrate comfort early
Palliative principles support symptom relief, communication, goals, caregiver support, and avoidance of burdensome low-value intervention throughout the disease, not only at the end of life.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- RxPrep 2023 Alzheimer Disease chapter, printed pages 881 through 885
- Alzheimer Association: Revised criteria for diagnosis and staging, 2024
- Alzheimer Association: DETeCD-ADRD clinical practice guideline
- Alzheimer Association: Blood-based biomarkers in specialty care, 2025
- FDA: KISUNLA prescribing information, 2025
- FDA: Aducanumab accelerated approval withdrawn November 2024